Minoxidil Responders vs. Non-Responders: The Biopsy Predictors

Approximately 30–40% of men show minimal response to topical minoxidil. The biological predictor — SULT1A1 sulfotransferase activity in the follicle — was identified in biopsy studies published in the 1990s and is now testable.

Minoxidil's reputation as the primary non-prescription hair loss treatment comes with a clinically significant caveat: a substantial proportion of men — estimates range from 30–40% in clinical series — do not achieve meaningful hair density response to topical formulations. The biological basis for this non-response is understood and now testable.

The prodrug mechanism

Minoxidil itself is pharmacologically inactive in the context of hair growth. Its activity requires intracellular conversion to minoxidil sulfate — the compound that opens ATP-sensitive potassium channels in smooth muscle cells of perifollicular vasculature and dermal papilla cells, producing the vasodilatory and growth-phase-extending effects.

This conversion is catalysed by sulfotransferase enzymes, primarily SULT1A1 (sulfotransferase family 1A, member 1), which is expressed in the outer root sheath of hair follicles. The enzyme transfers a sulfate group from PAPS (3'-phosphoadenosine-5'-phosphosulfate) to minoxidil, generating the active minoxidil sulfate metabolite locally.

SULT1A1 as the responder gate

Biopsy studies comparing responders and non-responders to topical minoxidil showed significantly higher SULT1A1 activity in the scalp follicles of responders. Low SULT1A1 expression in the follicle outer root sheath — whether due to genetic polymorphism, regulatory factors, or scalp-specific enzyme reduction — limits local minoxidil sulfate generation to sub-therapeutic concentrations regardless of topical dose applied.

Subsequent work found that SULT1A1 activity in scalp follicles correlates with a blood proxy — erythrocyte sulfotransferase activity. A positive blood assay or a scalp biopsy showing adequate SULT1A1 expression predicts topical response; low values predict non-response.

Oral minoxidil: the pathway around the gate

The pharmacological logic for oral minoxidil in non-responders is clear. Oral minoxidil is absorbed through the GI tract into systemic circulation. It is converted to minoxidil sulfate in the liver — where SULT1A1 activity is typically robust regardless of scalp enzyme levels — and the active metabolite is delivered to the follicle via systemic circulation. Scalp follicle SULT1A1 activity is not required when the active metabolite arrives via blood rather than local conversion.

This explains the clinical observation that some men who fail topical minoxidil respond meaningfully to oral formulations at doses that produce systemic exposure well above what topical application achieves. The route of delivery is the relevant variable, not the drug itself.